Apimeds Pharmaceuticals US APUS
NYSE APUS
$3.19 -0.22 (-6.30%)
As of: Oct 21, 2026 · 2:29 PM EDT

Apimeds Pharmaceuticals US (APUS) Common Equity (2023 - 2026)

Updated

Apimeds Pharmaceuticals US (APUS) posted Common Equity of $106.45 million for Q2 2026, up 993.2% from $9.74 million a year earlier.

Analysis

Apimeds Pharmaceuticals US (APUS) Common Equity (2023 - 2026) Analysis & Trends

At the end of FY2025, Apimeds Pharmaceuticals US's Common Equity came in at $153.35 million.

  • In prior years, Apimeds Pharmaceuticals US's Common Equity was -$1.36 million in FY2024 and $31,869 in FY2023.
  • Quarterly Common Equity has run from a low of -$1.76 million in Q1 2025 to a high of $153.35 million in Q4 2025 over five years.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Eli Lilly 1,135.59 Bn 1,104.17 Bn 19.71 Bn 33.88 Bn
2 Johnson & Johnson 616.92 Bn 535.45 Bn 17.26 Bn 84.97 Bn
3 AbbVie 501.52 Bn 474.63 Bn 12.70 Bn -5.94 Bn
4 Merck 367.36 Bn 321.74 Bn 12.21 Bn 41.98 Bn
5 Novartis Ag 297.93 Bn 261.92 Bn 11.24 Bn 41.95 Bn
6 Astrazeneca 261.45 Bn 235.14 Bn 12.86 Bn 50.37 Bn
7 Amgen 236.40 Bn 191.80 Bn 7.24 Bn 11.69 Bn
8 Gilead Sciences 190.72 Bn 164.92 Bn 6.22 Bn 11.83 Bn
9 Pfizer 169.43 Bn 116.08 Bn 10.94 Bn 85.49 Bn
10 Apimeds Pharmaceuticals US 5.52 Mn -14.12 Mn - 106.45 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 106.45 Mn
Dec 31, 2025 153.35 Mn
Sep 30, 2025 8.16 Mn
Jun 30, 2025 9.74 Mn
Mar 31, 2025 -1.76 Mn
Dec 31, 2024 -1.36 Mn
Sep 30, 2024 -1.05 Mn
Jun 30, 2024 -713,967.00
Mar 31, 2024 -264,604.00
Dec 31, 2023 31,869.00
API Access

Apimeds Pharmaceuticals US Common Equity API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=common-equity&ticker=APUS&period=max&api_key=YOUR_API_KEY